Novan Inc
F:6LUA
Novan Inc
Depreciation & Amortization
Novan Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Depreciation & Amortization
$2.8m
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Depreciation & Amortization
$7.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Depreciation & Amortization
$4.9B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
28%
|
|
|
Pfizer Inc
NYSE:PFE
|
Depreciation & Amortization
$6.7B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Depreciation & Amortization
$4.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Depreciation & Amortization
$1.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Depreciation & Amortization?
Depreciation & Amortization
2.8m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Depreciation & Amortization amounts to 2.8m USD.
What is Novan Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
14%
Over the last year, the Depreciation & Amortization growth was 708%. The average annual Depreciation & Amortization growth rates for Novan Inc have been 11% over the past three years , 14% over the past five years .
